234 related articles for article (PubMed ID: 30667544)
1. A pilot, layerwise, ex vivo evaluation of the antifungal efficacy of amorolfine 5% nail lacquer vs other topical antifungal nail formulations in healthy toenails.
Ghannoum M; Long L; Kunze G; Sarkany M; Osman-Ponchet H
Mycoses; 2019 Jun; 62(6):494-501. PubMed ID: 30667544
[TBL] [Abstract][Full Text] [Related]
2. Visualisation of penetration of topical antifungal drug substances through mycosis-infected nails by matrix-assisted laser desorption ionisation mass spectrometry imaging.
Endringer Pinto F; Bagger C; Kunze G; Joly-Tonetti N; Thénot JP; Osman-Ponchet H; Janfelt C
Mycoses; 2020 Aug; 63(8):869-875. PubMed ID: 32406142
[TBL] [Abstract][Full Text] [Related]
3. Application of cosmetic nail varnish does not affect the antifungal efficacy of amorolfine 5% nail lacquer in the treatment of distal subungual toenail onychomycosis: results of a randomised active-controlled study and in vitro assays.
Sigurgeirsson B; Ghannoum MA; Osman-Ponchet H; Kerrouche N; Sidou F
Mycoses; 2016 May; 59(5):319-26. PubMed ID: 26867498
[TBL] [Abstract][Full Text] [Related]
4. Penetration Profiles of Four Topical Antifungals in Mycotic Human Toenails Quantified by Matrix-Assisted Laser Desorption Ionization-Fourier Transform Ion Cyclotron Resonance Imaging.
Joly-Tonetti N; Legouffe R; Tomezyk A; Gumez C; Gaudin M; Bonnel D; Schaller M
Infect Dis Ther; 2024 Jun; 13(6):1269-1279. PubMed ID: 38704491
[TBL] [Abstract][Full Text] [Related]
5. Hydrosoluble medicated nail lacquers: in vitro drug permeation and corresponding antimycotic activity.
Monti D; Saccomani L; Chetoni P; Burgalassi S; Senesi S; Ghelardi E; Mailland F
Br J Dermatol; 2010 Feb; 162(2):311-7. PubMed ID: 19886884
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of 5% amorolfine nail lacquer in Neoscytalidium dimidiatum onychomycosis.
Bunyaratavej S; Leeyaphan C; Rujitharanawong C; Surawan TM; Muanprasat C; Matthapan L
J Dermatolog Treat; 2016 Aug; 27(4):359-63. PubMed ID: 26471716
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy and safety of amorolfine nail lacquer 5% in onychomycosis, once-weekly versus twice-weekly.
Reinel D; Clarke C
Clin Exp Dermatol; 1992 Sep; 17 Suppl 1():44-9. PubMed ID: 1458665
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of amorolfine 5% nail lacquer in combination with systemic antifungal agents for onychomycosis: A meta-analysis and systematic review.
Feng X; Xiong X; Ran Y
Dermatol Ther; 2017 May; 30(3):. PubMed ID: 28097731
[TBL] [Abstract][Full Text] [Related]
9. Penetration Profile of Terbinafine Compared to Amorolfine in Mycotic Human Toenails Quantified by Matrix-Assisted Laser Desorption Ionization-Fourier Transform Ion Cyclotron Resonance Imaging.
Joly-Tonetti N; Legouffe R; Tomezyk A; Gumez C; Gaudin M; Bonnel D; Schaller M
Infect Dis Ther; 2024 Jun; 13(6):1281-1290. PubMed ID: 38713301
[TBL] [Abstract][Full Text] [Related]
10. A randomized comparison of nail surface remanence of three nail lacquers, containing amorolfine 5%, ciclopirox 8% or tioconazole 28%, in healthy volunteers.
Sidou F; Soto P
Int J Tissue React; 2004; 26(1-2):17-24. PubMed ID: 15573688
[TBL] [Abstract][Full Text] [Related]
11. Patient-reported outcomes from two randomised studies comparing once-weekly application of amorolfine 5% nail lacquer to other methods of topical treatment in distal and lateral subungual onychomycosis.
Schaller M; Sigurgeirsson B; Sarkany M
Mycoses; 2017 Dec; 60(12):800-807. PubMed ID: 28925059
[TBL] [Abstract][Full Text] [Related]
12. Ciclopirox nail lacquer 8%: in vivo penetration into and through nails and in vitro effect on pig skin.
Ceschin-Roques CG; Hänel H; Pruja-Bougaret SM; Luc J; Vandermander J; Michel G
Skin Pharmacol; 1991; 4(2):89-94. PubMed ID: 1831626
[TBL] [Abstract][Full Text] [Related]
13. Amorolfine 5% Nail Lacquer Exhibits Potent Antifungal Activity Compared to Three Acid-Based Devices Indicated for the Treatment of Onychomycosis: An In Vitro Nail Penetration Assay.
Ghannoum M; Sevin K; Sarkany M
Dermatol Ther (Heidelb); 2016 Mar; 6(1):69-75. PubMed ID: 26833478
[TBL] [Abstract][Full Text] [Related]
14. Ciclopirox vs amorolfine: in vitro penetration into and permeation through human healthy nails of commercial nail lacquers.
Monti D; Tampucci S; Chetoni P; Burgalassi S; Mailland F
J Drugs Dermatol; 2014 Feb; 13(2):143-7. PubMed ID: 24509963
[TBL] [Abstract][Full Text] [Related]
15. Loceryl nail lacquer--realization of a new galenical approach to onychomycosis therapy.
Pittrof F; Gerhards J; Erni W; Klecak G
Clin Exp Dermatol; 1992 Sep; 17 Suppl 1():26-8. PubMed ID: 1458660
[TBL] [Abstract][Full Text] [Related]
16. Nail penetration and predicted mycological efficacy of an innovative hydrosoluble ciclopirox nail lacquer vs. a standard amorolfine lacquer in healthy subjects.
Monti D; Herranz U; Dal Bo L; Subissi A
J Eur Acad Dermatol Venereol; 2013 Feb; 27(2):e153-8. PubMed ID: 22449201
[TBL] [Abstract][Full Text] [Related]
17. Different physicochemical properties of antimycotic agents are relevant for penetration into and through human nails.
Neubert RH; Gensbügel C; Jäckel A; Wartewig S
Pharmazie; 2006 Jul; 61(7):604-7. PubMed ID: 16889067
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of topical resin lacquer, amorolfine and oral terbinafine for treating toenail onychomycosis: a prospective, randomized, controlled, investigator-blinded, parallel-group clinical trial.
Auvinen T; Tiihonen R; Soini M; Wangel M; Sipponen A; Jokinen JJ
Br J Dermatol; 2015 Oct; 173(4):940-8. PubMed ID: 26036329
[TBL] [Abstract][Full Text] [Related]
19. A multicentre, randomised, parallel-group, double-blind, vehicle-controlled and open-label, active-controlled study (versus amorolfine 5%), to evaluate the efficacy and safety of terbinafine 10% nail lacquer in the treatment of onychomycosis.
Blume-Peytavi U; Tosti A; Falqués M; Tamarit ML; Carreño C; Galván J; Tebbs V
Mycoses; 2022 Apr; 65(4):392-401. PubMed ID: 34752667
[TBL] [Abstract][Full Text] [Related]
20. The low keratin affinity of efinaconazole contributes to its nail penetration and fungicidal activity in topical onychomycosis treatment.
Sugiura K; Sugimoto N; Hosaka S; Katafuchi-Nagashima M; Arakawa Y; Tatsumi Y; Jo Siu W; Pillai R
Antimicrob Agents Chemother; 2014 Jul; 58(7):3837-42. PubMed ID: 24752277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
